Zai Lab (ZLAB) Earning Favorable News Coverage, Report Finds

Headlines about Zai Lab (NASDAQ:ZLAB) have been trending positive on Thursday, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Zai Lab earned a daily sentiment score of 0.25 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.1933989661353 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:

Several research firms have issued reports on ZLAB. BidaskClub upgraded Zai Lab from a “sell” rating to a “hold” rating in a research note on Thursday, March 22nd. Leerink Swann restated an “outperform” rating on shares of Zai Lab in a research note on Friday, March 23rd. Finally, JPMorgan Chase & Co. upgraded Zai Lab from a “neutral” rating to an “overweight” rating and set a $32.00 price objective for the company in a research report on Wednesday, February 14th.

Shares of NASDAQ:ZLAB traded up $0.45 during trading on Thursday, hitting $21.35. 47,697 shares of the company’s stock traded hands, compared to its average volume of 81,349. Zai Lab has a 52 week low of $19.80 and a 52 week high of $35.74.

COPYRIGHT VIOLATION NOTICE: This piece of content was first posted by BBNS and is owned by of BBNS. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The correct version of this piece of content can be viewed at https://baseballnewssource.com/2018/03/29/favorable-news-coverage-somewhat-unlikely-to-impact-zai-lab-zlab-stock-price/1971170.html.

Zai Lab Company Profile

Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases.

Insider Buying and Selling by Quarter for Zai Lab (NASDAQ:ZLAB)

Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.

 




Latest News

Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old
Major League Baseball is Back and Astros Favored to Repeat
Major League Baseball is Back and Astros Favored to Repeat
Jim Kaat: Baseball Would Be Helped by Shortening Game to Seven Innings
Jim Kaat: Baseball Would Be Helped by Shortening Game to Seven Innings


Leave a Reply

 
© 2006-2018 BBNS.